GSK RSV shot 43% effective against severe disease in third year
WEB3 hours ago · Oct 8 (Reuters) - GSK (GSK.L) said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the ...
GSK Says RSV Vaccine Offers Protection Over Three Seasons
WEB3 hours ago · 1:42. GSK Plc’s shot for respiratory syncytial virus provided protection across three seasons after vaccination, the company said Tuesday. The shot for older adults showed cumulative efficacy ...
Making an RSV Vaccine Was Hard. Getting People to Take It Is …
WEB4 days ago · New vaccines could help stem the spread of respiratory syncytial virus, but there are already huge inequities in access and uptake. US Centers for Disease Control data shows Latino people are ...
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · The US Food and Drug Administration approved the first vaccine against respiratory syncytial virus, known as RSV, and vaccines are in the works.
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
WEBMay 31, 2024 · mRESVIA (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.
FDA Approves New Drug to Prevent RSV in Babies and Toddlers
WEBToday, the U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and...
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of...
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ...
WEBApr 9, 2024 · ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk. The vaccine was well-tolerated and demonstrated an immune response non-inferior to adults aged 60 years and older
FDA approves RSV vaccine for adults ages 60 and up - NBC News
WEBMay 3, 2023 · Researchers first attempted to develop a vaccine for respiratory syncytial virus roughly 60 years ago. In a late-stage clinical trial, the single-dose shot lowered the risk of symptomatic illness...
‘A good day’: FDA approves world’s first RSV vaccine - Nature
WEBMay 3, 2023 · The US Food and Drug Administration (FDA) has approved GSK’s vaccine against respiratory syncytial virus (RSV) for use in people aged 60 years and older. This is the first RSV vaccine to gain...